IMNN — Imunon Cashflow Statement
0.000.00%
- $21.73m
- $18.86m
Annual cashflow statement for Imunon, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -21.5 | -20.8 | -35.9 | -19.5 | -18.6 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 5.54 | 3.74 | 10.9 | 2.02 | 0.893 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.386 | -0.362 | 1.89 | -2.07 | -2.65 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -15.6 | -16.2 | -23.1 | -19 | -18.9 |
Capital Expenditures | -0.019 | -0.312 | -0.268 | -0.452 | -0.03 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 7.94 | -29.8 | 8.55 | 11.5 | 9.86 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 7.92 | -30.1 | 8.28 | 11 | 9.83 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 18 | 54.8 | 6.72 | -3.64 | 9.06 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 10.3 | 8.42 | -8.09 | -11.7 | 0.034 |